Bispecific tetravalent antibody targeting EGFR and her3

EP4392457A4Pending Publication Date: 2025-10-15SYSTIMMUNE INC
2 Cites 0 Cited by

Patent Information

Application Number
EP2022862268
Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-08-25
Filing Date
2022-08-25
Publication Date
2025-10-15

AI Technical Summary

Technical Problem

Current therapeutic approaches targeting EGFR and HER2 signaling pathways in cancer treatment face challenges due to acquired resistance, particularly the upregulation of HER3, leading to limited long-term benefits and resistance in patients.

Method used

Development of bispecific tetravalent antibodies that simultaneously target EGFR and HER3, comprising an IgG moiety with two heavy chains and two scFv moieties covalently connected, enhancing binding specificity and stability to inhibit oncogenic signaling.

Benefits of technology

The bispecific tetravalent antibodies effectively inhibit EGFR/HER3 dimerization, overcoming resistance to EGFR inhibitor treatments and providing superior therapeutic efficacy by maintaining strong binding affinity and stability, thereby inhibiting tumor cell proliferation.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A bispecific antibody comprises two sets of heavy and light chains, wherein each set of the heavy chain and the light chain form a Fab region having a binding specificity to EGFR; the antibody and further comprises a scFv domain covalently linked to N -terminal of the heavy chain, N -terminal of the light chain, or C-terminal of the light chain, wherein the scFv domain has a binding specificity to HER3.
Need to check novelty before this filing date? Find Prior Art